Malcolm Ward

Malcolm Ward

Auto-generated profile, based on publicly available information

Malcolm Ward

Proteome Sciences plc, London, UK

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
DHDiane P. Hanger
Diane P. Hanger
HBHelen L. Byers
Helen L. Byers
SWSelina Wray
Selina Wray
KLKit-Yi Leung
Kit-Yi Leung
MSMalcolm J. Saxton
Malcolm J. Saxton
BABrian H. Anderton
Brian H. Anderton
Tau in Alzheimer disease brain is highly phosphorylated and aggregated into paired helical filaments comprising characteristic neurofibrillary tangles. Here we have analyzed insoluble Tau (PHF-tau) extracted from Alzheimer brain by mass spectrometry and identified 11 novel phosphorylation sites, 10 of which were assigned unambiguously to specific amino acid residues. This brings the number of directly identified sites in PHF-tau to 39, with an additional six sites indicated by reactivity with phosphospecific antibodies to Tau. We also identified five new phosphorylation sites in soluble Tau from control adult human brain, bringing the total number of reported sites to nine. To assess which kinases might be responsible for Tau phosphorylation, we used mass spectrometry to determine which sites were phosphorylated in vitro by several kinases. Casein kinase 1δ and glycogen synthase kinase-3β were each found to phosphorylate numerous sites, and each kinase phosphorylated at least 15 sites that are also phosphorylated in PHF-tau from Alzheimer brain. A combination of casein kinase 1δ and glycogen synthase kinase-3β activities could account for over three-quarters of the serine/threonine phosphorylation sites identified in PHF-tau, indicating that casein kinase 1δ may have a role, together with glycogen synthase kinase-3β, in the pathogenesis of Alzheimer disease.

1 November 2006 in Brain
Verified
Journal Article
Open access
PDF file
AHA. Hye
A. Hye
SLS. Lynham
S. Lynham
MTM. Thambisetty
M. Thambisetty
MCM. Causevic
M. Causevic
JCJ. Campbell
J. Campbell
SLS. Lovestone
S. Lovestone
Alzheimer's disease is a common and devastating disease for which there is no readily available biomarker to aid diagnosis or to monitor disease progression. Biomarkers have been sought in CSF but no previous study has used two-dimensional gel electrophoresis coupled with mass spectrometry to seek biomarkers in peripheral tissue. We performed a case–control study of plasma using this proteomics approach to identify proteins that differ in the disease state relative to aged controls. For discovery-phase proteomics analysis, 50 people with Alzheimer's dementia were recruited through secondary services and 50 normal elderly controls through primary care. For validation purposes a total of 511 subjects with Alzheimer's disease and other neurodegenerative diseases and normal elderly controls were examined. Image analysis of the protein distribution of the gels alone identifies disease cases with 56% sensitivity and 80% specificity. Mass spectrometric analysis of the changes observed in two-dimensional electrophoresis identified a number of proteins previously implicated in the disease pathology, including complement factor H (CFH) precursor and α-2-macroglobulin (α-2M). Using semi-quantitative immunoblotting, the elevation of CFH and α-2M was shown to be specific for Alzheimer's disease and to correlate with disease severity although alternative assays would be necessary to improve sensitivity and specificity. These findings suggest that blood may be a rich source for biomarkers of Alzheimer's disease and that CFH, together with other proteins such as α-2M may be a specific markers of this illness.

1 July 2010 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
MTMadhav Thambisetty
Madhav Thambisetty
ASAndrew Simmons
Andrew Simmons
LVLatha Velayudhan
Latha Velayudhan
AHAbdul Hye
Abdul Hye
JCJames Campbell
James Campbell
SLSimon Lovestone
Simon Lovestone
Peripheral compartments including blood and cerebrospinal fluid exhibit signals reflecting neuropathological changes in Alzheimer disease (AD).1,2 In cerebrospinal fluid, these include a decrease in amyloid-β peptide (Aβ) and an increase in total and phosphorylated tau concentrations,3 reflecting amyloid sequestration as plaques and neurofibrillary degeneration, respectively.4,5 Similarly, while numerous articles suggest that plasma concentrations of several metabolites and proteins might represent responses to neuropathological changes in AD,6-11 these findings have not been conclusively replicated.12 A limitation of such studies may be their reliance upon demonstrating changes between affected and unaffected people, a design of study that might identify secondary changes lacking relevance to core disease biology.

1 March 2007 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
SGSarah Gallois-Montbrun
Sarah Gallois-Montbrun
BKBeatrice Kramer
Beatrice Kramer
CSChad M. Swanson
Chad M. Swanson
HBHelen Byers
Helen Byers
SLSteven Lynham
Steven Lynham
MMMichael H. Malim
Michael H. Malim
Members of the APOBEC (apolipoproteinBmRNA-editing enzymecatalytic polypeptide 1-like) family of cytidine deaminases inhibit host cell genome invasion by exogenous retroviruses and endogenous retrotransposons. Because these enzymes can edit DNA or RNA and potentially mutate cellular targets, their activities are presumably regulated; for instance, APOBEC3G (A3G) recruitment into high-molecular-weight ribonucleoprotein (RNP) complexes has been shown to suppress its enzymatic activity. We used tandem affinity purification together with mass spectrometry (MS) to identify protein components within A3G-containing RNPs. We report that numerous cellular RNA-binding proteins with diverse roles in RNA function, metabolism, and fate determination are present in A3G RNPs but that most interactions with A3G are mediated via binding to shared RNAs. Confocal microscopy demonstrated that substantial quantities of A3G localize to cytoplasmic microdomains that are known as P bodies and stress granules (SGs) and are established sites of RNA storage and metabolism. Indeed, subjecting cells to stress induces the rapid redistribution of A3G and a number of P-body proteins to SGs. Among these proteins are Argonaute 1 (Ago1) and Argonaute 2 (Ago2), factors that are important for RNA silencing and whose interactions with A3G are resistant to RNase treatment. Together, these findings reveal that A3G associates with RNPs that are found throughout the cytosol as well as in discrete microdomains. We also speculate that the interplay between A3G, RNA-silencing pathways, and cellular sites of RNA metabolism may contribute to A3G's role as an inhibitor of retroelement mobility and as a possible regulator of cellular RNA function.

7 June 2007 in Journal of Proteome Research
Verified
Journal Article
Closed access
†D† Annette Dalrymple
† Annette Dalrymple
EWEdward Wild
Edward Wild
RJRichard Joubert
Richard Joubert
KSKirupa Sathasivam
Kirupa Sathasivam
B Maria Björkqvist
Maria Björkqvist
GKGeoff Keir
Geoff Keir

7 July 2014 in Alzheimer's & Dementia
Verified
Journal Article
Open access
AHAbdul Hye
Abdul Hye
JRJoanna Riddoch‐Contreras
Joanna Riddoch‐Contreras
ABAlison L. Baird
Alison L. Baird
NANicholas Ashton
Nicholas Ashton
CBChantal Bazenet
Chantal Bazenet
SLSimon Lovestone
Simon Lovestone
Background: The study aimed to validate previously discovered plasma biomarkers associated with AD, using a design based on imaging measures as surrogate for disease severity and assess their prognostic value in predicting conversion to dementia.Methods: Three multicenter cohorts of cognitively healthy elderly, mild cognitive impairment (MCI), and AD participants with standardized clinical assessments and structural neuroimaging measures were used. Twenty‐six candidate proteins were quantified in 1148 subjects using multiplex (xMAP) assays.Results: Sixteen proteins correlated with disease severity and cognitive decline. Strongest associations were in the MCI group with a panel of 10 proteins predicting progression to AD (accuracy 87%, sensitivity 85%, and specificity 88%).Conclusions: We have identified 10 plasma proteins strongly associated with disease severity and disease progression. Such markers may be useful for patient selection for clinical trials and assessment of patients with predisease subjective memory complaints.